ated with increased sIL-2Ra [4, 7] . Some investigators have suggested that the serum sIL-2Ra level may be a prognostic factor for selecting appropriate treatment of NHL and for determining the clinical outcome in aggressive NHL [8] [9] [10] [11] .983). The measurement range was from 0 to 16,500 U/mL, and the detection limit was 10 U/mL. The serum sIL-2Ra level was considered either high or low by comparing it with the median measurement level of 2,000 U/mL, as reported elsewhere [8, 11] . The differences between groups in terms of median values were tested using the nonparametric Mann-Whitney U-test. The overall survival was calculated from the date of diagnosis until death from any cause. The survival curve was estimated using the Kaplan-Meier method, and survival difference was determined using the log-rank test. Cox' s proportionalhazards regression analysis was applied to estimate the independency of prognostic parameters. We subjected the pretreatment characteristics to univariate analysis. Next, we performed a multivariate analysis to define the prognostic impact of selected parameters that were found to be significant in the univariate analysis including the sIL-2Ra level. We set the level of statistical significance at P<0.05. (Fig. 2) . However, 3 patients who did not achieve remission because of recurrence or progressive disease showed sustained high levels of sIL-2Ra of above 2,000 U/mL (Fig. 3) . There was one exceptional case that showed radiographic remission along with an elevated sIL-2Ra level of 6,508 U/mL, but the pretreatment level in this case was 569 U/mL. Soon after, brain involvement of lymphoma was found. Univariate analysis showed that the overall survival rate was significantly lower in patients with B symptoms and high sIL-2Ra levels (log-rank test, P<0.05) ( Table 2 , Fig. 4 ). Multivariate analysis showed that B symptoms were an independent prognostic factor for overall survival (P<0.05). In the present study, it was found that the sIL-2Ra level may be prognostically useful for NHL patients at the time of diagnosis and for monitoring disease progress continuously. As shown in Fig. 1 Overall survival rate Months sil-2Ra <2,000 U/mL sil-2Ra ≥2,000 U/mL Fig. 4 . Overall survival curves for non-Hodgkin's lymphoma patients in relation to soluble interleukin-2 receptor alpha (sIL-2Ra) level; overall survival curves according to low (<2,000 U/mL) versus high (≥2,000 U/mL) level of sIL-2Ra (Log-rank test, P=0.041).
or diffuse large B-cell lymphoma at the time of diagnosis, and a high level of this cytokine receptor could be a prognostic factor, which could aid in predicting the outcome of these diseases in patients [8, 9, 11] . Others have suggested using serum sIL-2Ra levels to monitor the therapeutic response in anaplastic large cell lymphoma or malignant lymphoma [2, 10, 12] . Our data showed that the sIL-2Ra level provides valuable information for better management of patients with NHL and can be used as a biomarker to predict prognosis and to monitor disease activity. In the one case with radiologic remission, the sIL-2Ra levels were elevated and brain involvement of lymphoma was observed.
This finding was similar to that of Yoshida and Morii who observed increased levels of sIL-2Ra in malignant brain tumors [13] , which could be caused by pathological changes occurring before radiological changes.
This study had several limitations. First, we targeted various histological types of NHL to evaluate the significance of sIL-2Ra as a comprehensive prognostic marker, similar to IPI. Second, in multivariate analysis, a high level of sIL-2Ra was not an independent prognostic factor. Therefore, a longer period of observation and patients with lymphoma of a specific histological type should be studied in order to clearly understand the prognostic impact of sIL2Ra. Further, the sIL-2Ra level might be a non-specific biomarker that is increased in immunologic or tumorigenic disease conditions such as rheumatoid arthritis or non-small cell lung cancers [14, 15] . However, Sakata et al. [16] reported that the serum sIL-2Ra level is increased more in invasive cancers than in activated immune states. Huang et al.
[17] also reported that in malignant tumors, sIL-2Ra is produced through a pathway other than the one through which it is produced in conditions involving T-cell upregulation. 
